Ethics of a partially effective dengue vaccine: Lessons from the Philippines

Dengvaxia, a chimeric yellow fever tetravalent dengue vaccine developed by SanofiPasteur is widely licensed in dengue-endemic countries. In a large cohort study Dengvaxia was found to partially protect children who had prior dengue virus (DENV) infections but sensitized seronegative children to brea...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Vaccine
Main Authors: Halstead, Scott B., Katzelnick, Leah C., Russell, Philip K., Markoff, Lewis, Aguiar, Maira, Dans, Leonila R., Dans, Antonio L.
Formato: Artigo
Idioma:Inglês
Publicado em: Elsevier Ltd. 2020
Assuntos:
Commentary
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7347470/
https://ncbi.nlm.nih.gov/pubmed/32654899
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.vaccine.2020.06.079
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados